Shamburg News · 8-K/A filed Nov 18, 2026, 4:47 PM EST

Voyager Therapeutics Reports Third Quarter 2026 Financial and Operating Results

VYGR · Voyager Therapeutics, Inc.

  • Earnings
  • Materiality: high

Voyager Therapeutics reported third quarter 2026 results, with collaboration revenue of $4.0 million and a net loss of $24.7 million, or $0.40 per share. Research and development expenses were $24.4 million and general and administrative expenses were $6.1 million for the quarter. Cash, cash equivalents and marketable securities were $132.1 million as of September 30, 2026, which the company expects to fund operations into the second quarter of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K/A, Item 2.02, accession 0001193125-26-467226.

Written from the filing by Shamburg Markets. Figures are as reported by the company.